Macher, S.
Bsteh, G.
Pataraia, E.
Berger, T.
Höftberger, R.
Rommer, P. S. http://orcid.org/0000-0001-5209-6647
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 21 November 2022
Accepted: 20 April 2023
First Online: 6 June 2023
Conflict of interest
: S. Macher has nothing to disclose with respect to this manuscript, G. Bsteh has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Roche and Teva. E. Pataraia has nothing to disclose with respect to this manuscript, T. Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from Almirall, Bayer, Biogen, Biologix, Bionorica, Celgene/BMS, GSK, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, Teva and TG Pharmaceuticals. His institution has received financial support in the past 12 months by unrestricted research grants (Biogen, Celgene/BMS, Merck, Novartis, Sanofi-Genzyme, Teva) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. P.S. Rommer has received honoraria for consultancy/speaking from AbbVie, Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sandoz, Sanofi-Genzyme and has received research grants from Amicus, Biogen, Merck and Roche. R. Höftberger has received speaker honoraria from Novartis and Biogen.